OUR MISSION
Ground Breaking Biomarker Solutions
Multinostics provides a unique, proprietary, and integrated easy-to-use eye testing device comprised of both hardware and software for the early detection of Alzheimer’s disease (AD) so that therapies can be started immediately to improve quality of life.
Eye Biomarkers carry the potential to detect AD early
Accurate diagnosis
Cost-effective and Instantaneous
Cost-effective and Instantaneous
Studies show that cognitive impairment may remain unrecognized in up to 80% of affected patients in primary care.
Cost-effective and Instantaneous
Cost-effective and Instantaneous
Cost-effective and Instantaneous
The costs of treatment and care for these patients are projected to increase from the estimated 203 billion USD to the whopping 1.2 trillion USD per year in the United States by the year 2050.
Portable and ubiquitous
Cost-effective and Instantaneous
Portable and ubiquitous
In the quest for gold standards for Alzheimer's disease assessment, there is a growing interest in identifying non-invasive and accessible biomarkers, which harness advances in portable and ubiquitous solutions.